世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

同種幹細胞市場（タイプ：非修飾幹細胞移植、T細胞欠失移植、臍帯血移植、ドナーリンパ球輸注[DLI]）-世界産業分析、規模、シェア、成長、動向、予測、2023-2031年


Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

同種幹細胞市場 - レポートの範囲 TMRの世界同種幹細胞市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ 		2023年8月11日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		204 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

同種幹細胞市場 - レポートの範囲
TMRの世界同種幹細胞市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の同種幹細胞市場の収益を提供します。また、2023年から2031年までの世界の同種幹細胞市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、同種幹細胞市場を理解した。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストはトップダウンアプローチとボトムアップアプローチを組み合わせて、世界の同種幹細胞市場の様々な属性を調査した。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、同レポートは、世界の同種幹細胞市場における競争ダイナミクスの変化に光を投げかけている。これらは、既存の市場関係者だけでなく、世界の同種幹細胞市場への参入に関心のある企業にとっても貴重なツールとなります。

同レポートでは、世界の同種幹細胞市場の競争環境について掘り下げている。世界の同種幹細胞市場で事業を展開する主要企業が特定され、その各企業が様々な属性でプロファイリングされている。会社概要、財務状況、最近の動向、SWOTは本レポートで紹介されている世界の同種幹細胞市場におけるプレイヤーの属性である。

同種幹細胞の世界市場レポートが回答した主要な質問
- 予測期間中の全地域における同種幹細胞の売上高/売上収益は？
- 世界の同種幹細胞市場におけるビジネスチャンスは？
- 市場における主な促進要因、阻害要因、機会、脅威は何か？
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか？
- 2031年に世界で最も高い収益を上げると予測されるセグメントは？
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは？
- 世界市場で事業を展開する各企業の市場ポジションは？

同種幹細胞市場 - 調査目的と調査アプローチ
同種幹細胞の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーや流通業者、製品承認に関する規制シナリオについて詳細に解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。

本レポートでは、世界の同種幹細胞市場を製品、エンドユーザー、地域の観点から分析している。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載している。このような貴重な洞察により、市場関係者は世界の同種幹細胞市場への投資について、十分な情報に基づいたビジネス上の意思決定を行うことが可能となる。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allogeneic Stem Cell Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
    5.2. Technological Advancements
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Type, 2017-2031
        6.3.1. Unmodified Stem Cell Transplant
        6.3.2. T-cell Depleted Transplant
        6.3.3. Cord Blood Transplant
        6.3.4. Donor Lymphocyte Infusion (DLI)
    6.4. Market Attractiveness Analysis, by Type
7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Cell Source, 2017-2031
        7.3.1. Bone Marrow
        7.3.2. Peripheral Blood Stem Cell (PBSC)
        7.3.3. Umbilical Cord Blood
        7.3.4. Adipose Tissue
        7.3.5. Others
    7.4. Market Attractiveness Analysis, by Cell Source
8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Musculoskeletal Disease
        8.3.2. Cardiovascular Disease
        8.3.3. Autoimmune Disease
        8.3.4. Cancer
        8.3.5. GvHD
        8.3.6. Others
    8.4. Market Attractiveness Analysis, by Application
9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospital
        9.3.2. Ambulatory Surgical Center
        9.3.3. Others
    9.4. Market Attractiveness Analysis, by End-user
10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Allogeneic Stem Cell Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type, 2017-2031
        11.2.1. Unmodified Stem Cell Transplant
        11.2.2. T-cell Depleted Transplant
        11.2.3. Cord Blood Transplant
        11.2.4. Donor Lymphocyte Infusion (DLI)
    11.3. Market Value Forecast, by Cell Source, 2017-2031
        11.3.1. Bone Marrow
        11.3.2. Peripheral Blood Stem Cell (PBSC)
        11.3.3. Umbilical Cord Blood
        11.3.4. Adipose Tissue
        11.3.5. Others
    11.4. Market Value Forecast, by Application, 2017-2031
        11.4.1. Musculoskeletal Disease
        11.4.2. Cardiovascular Disease
        11.4.3. Autoimmune Disease
        11.4.4. Cancer
        11.4.5. GvHD
        11.4.6. Others
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospital
        11.5.2. Ambulatory Surgical Center
        11.5.3. Others
    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Type
        11.7.2. By Cell Source
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country/Sub-region
12. Europe Allogeneic Stem Cell Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type, 2017-2031
        12.2.1. Unmodified Stem Cell Transplant
        12.2.2. T-cell Depleted Transplant
        12.2.3. Cord Blood Transplant
        12.2.4. Donor Lymphocyte Infusion (DLI)
    12.3. Market Value Forecast, by Cell Source, 2017-2031
        12.3.1. Bone Marrow
        12.3.2. Peripheral Blood Stem Cell (PBSC)
        12.3.3. Umbilical Cord Blood
        12.3.4. Adipose Tissue
        12.3.5. Others
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Musculoskeletal Disease
        12.4.2. Cardiovascular Disease
        12.4.3. Autoimmune Disease
        12.4.4. Cancer
        12.4.5. GvHD
        12.4.6. Others
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospital
        12.5.2. Ambulatory Surgical Center
        12.5.3. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Type
        12.7.2. By Cell Source
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type, 2017-2031
        13.2.1. Unmodified Stem Cell Transplant
        13.2.2. T-cell Depleted Transplant
        13.2.3. Cord Blood Transplant
        13.2.4. Donor Lymphocyte Infusion (DLI)
    13.3. Market Value Forecast, by Cell Source, 2017-2031
        13.3.1. Bone Marrow
        13.3.2. Peripheral Blood Stem Cell (PBSC)
        13.3.3. Umbilical Cord Blood
        13.3.4. Adipose Tissue
        13.3.5. Others
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Musculoskeletal Disease
        13.4.2. Cardiovascular Disease
        13.4.3. Autoimmune Disease
        13.4.4. Cancer
        13.4.5. GvHD
        13.4.6. Others
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospital
        13.5.2. Ambulatory Surgical Center
        13.5.3. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Type
        13.7.2. By Cell Source
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Allogeneic Stem Cell Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type, 2017-2031
        14.2.1. Unmodified Stem Cell Transplant
        14.2.2. T-cell Depleted Transplant
        14.2.3. Cord Blood Transplant
        14.2.4. Donor Lymphocyte Infusion (DLI)
    14.3. Market Value Forecast, by Cell Source, 2017-2031
        14.3.1. Bone Marrow
        14.3.2. Peripheral Blood Stem Cell (PBSC)
        14.3.3. Umbilical Cord Blood
        14.3.4. Adipose Tissue
        14.3.5. Others
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Musculoskeletal Disease
        14.4.2. Cardiovascular Disease
        14.4.3. Autoimmune Disease
        14.4.4. Cancer
        14.4.5. GvHD
        14.4.6. Others
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospital
        14.5.2. Ambulatory Surgical Center
        14.5.3. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Type
        14.7.2. By Cell Source
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type, 2017-2031
        15.2.1. Unmodified Stem Cell Transplant
        15.2.2. T-cell Depleted Transplant
        15.2.3. Cord Blood Transplant
        15.2.4. Donor Lymphocyte Infusion (DLI)
    15.3. Market Value Forecast, by Cell Source, 2017-2031
        15.3.1. Bone Marrow
        15.3.2. Peripheral Blood Stem Cell (PBSC)
        15.3.3. Umbilical Cord Blood
        15.3.4. Adipose Tissue
        15.3.5. Others
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Musculoskeletal Disease
        15.4.2. Cardiovascular Disease
        15.4.3. Autoimmune Disease
        15.4.4. Cancer
        15.4.5. GvHD
        15.4.6. Others
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospital
        15.5.2. Ambulatory Surgical Center
        15.5.3. Others
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Type
        15.7.2. By Cell Source
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Mesoblast Limited
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Gamida Cell Ltd.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Novartis International AG
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Cellectis SA
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Magenta Therapeutics Inc.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Fate Therapeutics Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Cynata Therapeutics Limited
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Kiadis Pharma N.V.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Takeda Pharmaceutical Company Limited
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. JCR Pharmaceuticals Co., Ltd.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Pluristem Therapeutics Inc.
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Celularity Inc.
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. Lineage Cell Therapeutics Inc.
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
        16.3.14. Nohla Therapeutics Inc.
            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.14.2. Product Portfolio
            16.3.14.3. Financial Overview
            16.3.14.4. SWOT Analysis
            16.3.14.5. Strategic Overview
        16.3.15. Orchard Therapeutics plc
            16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.15.2. Product Portfolio
            16.3.15.3. Financial Overview
            16.3.15.4. SWOT Analysis
            16.3.15.5. Strategic Overview
        16.3.16. Other Prominent Players
            16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.16.2. Product Portfolio
            16.3.16.3. Financial Overview
            16.3.16.4. SWOT Analysis
            16.3.16.5. Strategic Overview

　

ページTOPに戻る


　

Summary

Allogeneic Stem Cell Market – Scope of Report
TMR’s report on the global allogeneic stem cell market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allogeneic stem cell market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allogeneic stem cell market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the allogeneic stem cell market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allogeneic stem cell market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allogeneic stem cell market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allogeneic stem cell market.

The report delves into the competitive landscape of the global allogeneic stem cell market. Key players operating in the global allogeneic stem cell market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allogeneic stem cell market profiled in this report.

Key Questions Answered in Global Allogeneic Stem Cell Market Report
• What is the sales/revenue generated by allogeneic stem cell across all regions during the forecast period?
• What are the opportunities in the global allogeneic stem cell market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Allogeneic Stem Cell Market – Research Objectives and Research Approach
The comprehensive report on the global allogeneic stem cell market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allogeneic stem cell market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allogeneic stem cell market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allogeneic Stem Cell Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
    5.2. Technological Advancements
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Type, 2017-2031
        6.3.1. Unmodified Stem Cell Transplant
        6.3.2. T-cell Depleted Transplant
        6.3.3. Cord Blood Transplant
        6.3.4. Donor Lymphocyte Infusion (DLI)
    6.4. Market Attractiveness Analysis, by Type
7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Cell Source, 2017-2031
        7.3.1. Bone Marrow
        7.3.2. Peripheral Blood Stem Cell (PBSC)
        7.3.3. Umbilical Cord Blood
        7.3.4. Adipose Tissue
        7.3.5. Others
    7.4. Market Attractiveness Analysis, by Cell Source
8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Musculoskeletal Disease
        8.3.2. Cardiovascular Disease
        8.3.3. Autoimmune Disease
        8.3.4. Cancer
        8.3.5. GvHD
        8.3.6. Others
    8.4. Market Attractiveness Analysis, by Application
9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospital
        9.3.2. Ambulatory Surgical Center
        9.3.3. Others
    9.4. Market Attractiveness Analysis, by End-user
10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Allogeneic Stem Cell Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type, 2017-2031
        11.2.1. Unmodified Stem Cell Transplant
        11.2.2. T-cell Depleted Transplant
        11.2.3. Cord Blood Transplant
        11.2.4. Donor Lymphocyte Infusion (DLI)
    11.3. Market Value Forecast, by Cell Source, 2017-2031
        11.3.1. Bone Marrow
        11.3.2. Peripheral Blood Stem Cell (PBSC)
        11.3.3. Umbilical Cord Blood
        11.3.4. Adipose Tissue
        11.3.5. Others
    11.4. Market Value Forecast, by Application, 2017-2031
        11.4.1. Musculoskeletal Disease
        11.4.2. Cardiovascular Disease
        11.4.3. Autoimmune Disease
        11.4.4. Cancer
        11.4.5. GvHD
        11.4.6. Others
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospital
        11.5.2. Ambulatory Surgical Center
        11.5.3. Others
    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Type
        11.7.2. By Cell Source
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country/Sub-region
12. Europe Allogeneic Stem Cell Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type, 2017-2031
        12.2.1. Unmodified Stem Cell Transplant
        12.2.2. T-cell Depleted Transplant
        12.2.3. Cord Blood Transplant
        12.2.4. Donor Lymphocyte Infusion (DLI)
    12.3. Market Value Forecast, by Cell Source, 2017-2031
        12.3.1. Bone Marrow
        12.3.2. Peripheral Blood Stem Cell (PBSC)
        12.3.3. Umbilical Cord Blood
        12.3.4. Adipose Tissue
        12.3.5. Others
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Musculoskeletal Disease
        12.4.2. Cardiovascular Disease
        12.4.3. Autoimmune Disease
        12.4.4. Cancer
        12.4.5. GvHD
        12.4.6. Others
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospital
        12.5.2. Ambulatory Surgical Center
        12.5.3. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Type
        12.7.2. By Cell Source
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type, 2017-2031
        13.2.1. Unmodified Stem Cell Transplant
        13.2.2. T-cell Depleted Transplant
        13.2.3. Cord Blood Transplant
        13.2.4. Donor Lymphocyte Infusion (DLI)
    13.3. Market Value Forecast, by Cell Source, 2017-2031
        13.3.1. Bone Marrow
        13.3.2. Peripheral Blood Stem Cell (PBSC)
        13.3.3. Umbilical Cord Blood
        13.3.4. Adipose Tissue
        13.3.5. Others
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Musculoskeletal Disease
        13.4.2. Cardiovascular Disease
        13.4.3. Autoimmune Disease
        13.4.4. Cancer
        13.4.5. GvHD
        13.4.6. Others
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospital
        13.5.2. Ambulatory Surgical Center
        13.5.3. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Type
        13.7.2. By Cell Source
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Allogeneic Stem Cell Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type, 2017-2031
        14.2.1. Unmodified Stem Cell Transplant
        14.2.2. T-cell Depleted Transplant
        14.2.3. Cord Blood Transplant
        14.2.4. Donor Lymphocyte Infusion (DLI)
    14.3. Market Value Forecast, by Cell Source, 2017-2031
        14.3.1. Bone Marrow
        14.3.2. Peripheral Blood Stem Cell (PBSC)
        14.3.3. Umbilical Cord Blood
        14.3.4. Adipose Tissue
        14.3.5. Others
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Musculoskeletal Disease
        14.4.2. Cardiovascular Disease
        14.4.3. Autoimmune Disease
        14.4.4. Cancer
        14.4.5. GvHD
        14.4.6. Others
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospital
        14.5.2. Ambulatory Surgical Center
        14.5.3. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Type
        14.7.2. By Cell Source
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type, 2017-2031
        15.2.1. Unmodified Stem Cell Transplant
        15.2.2. T-cell Depleted Transplant
        15.2.3. Cord Blood Transplant
        15.2.4. Donor Lymphocyte Infusion (DLI)
    15.3. Market Value Forecast, by Cell Source, 2017-2031
        15.3.1. Bone Marrow
        15.3.2. Peripheral Blood Stem Cell (PBSC)
        15.3.3. Umbilical Cord Blood
        15.3.4. Adipose Tissue
        15.3.5. Others
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Musculoskeletal Disease
        15.4.2. Cardiovascular Disease
        15.4.3. Autoimmune Disease
        15.4.4. Cancer
        15.4.5. GvHD
        15.4.6. Others
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospital
        15.5.2. Ambulatory Surgical Center
        15.5.3. Others
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Type
        15.7.2. By Cell Source
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Mesoblast Limited
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Gamida Cell Ltd.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Novartis International AG
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Cellectis SA
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Magenta Therapeutics Inc.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Fate Therapeutics Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Cynata Therapeutics Limited
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Kiadis Pharma N.V.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Takeda Pharmaceutical Company Limited
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. JCR Pharmaceuticals Co., Ltd.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Pluristem Therapeutics Inc.
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Celularity Inc.
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. Lineage Cell Therapeutics Inc.
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
        16.3.14. Nohla Therapeutics Inc.
            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.14.2. Product Portfolio
            16.3.14.3. Financial Overview
            16.3.14.4. SWOT Analysis
            16.3.14.5. Strategic Overview
        16.3.15. Orchard Therapeutics plc
            16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.15.2. Product Portfolio
            16.3.15.3. Financial Overview
            16.3.15.4. SWOT Analysis
            16.3.15.5. Strategic Overview
        16.3.16. Other Prominent Players
            16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.16.2. Product Portfolio
            16.3.16.3. Financial Overview
            16.3.16.4. SWOT Analysis
            16.3.16.5. Strategic Overview

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Transparency Market Research社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（stem cell）の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ（Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20　10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.